Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Moderna and Pfizer raise the bar for COVID-19 vaccines and may ward off competing candidates in development

Following the news that Moderna has announced its COVID-19 vaccine, mRNA-1273, is 94.5% effective in first interim data readout; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology at GlobalData, a leading data and analytics company, offers his view: “While the efficacy of Moderna’s offering is slightly higher than that reported for Pfizer/BioNTech’s candidate, the […]
Read more

Diabetes market continues to evolve rapidly

Across the seven major markets* (7MM), the diagnosed prevalence of type 1 and 2 diabetes (T1D) was approximately 3.7 million and 49.7 million, respectively, in 2020 – according to data and analytics company GlobalData. This is expected to grow to more than 4.3 million by 2025 for Type 1 and 54.4 million for Type 2 […]
Read more

Avastin and Tecentriq combination to take over standard of care in hepatocellular carcinoma, says GlobalData

Following the string of approvals this year for Roche’s combination of Avastin (bevacizumab) and Tecentriq (atezolizumab), key opinion leaders interviewed by GlobalData from the five major European pharmaceutical markets (5EU*) and China have noted that the majority of patients would receive Avastin plus Tecentriq in the first-line setting. This offers a major competition to current […]
Read more

Pfizer and BioNTech’s final Phase III COVID-19 vaccine analysis could decrease by 10 points from interim 90% data; vaccine could require testing to screen prior infection but rationale still theoretical

With Pfizer and BioNTech announcing that a Phase III trial investigating the BNT162b2 vaccine to be 90% effective in preventing symptomatic COVID-19 in participants without evidence of prior infection; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:   “The final Phase III efficacy analysis of Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 […]
Read more

Key players in breast cancer space engage effectively with Japanese patients through unbranded digital strategies, says GlobalData

In Japan, the breast cancer treatment landscape consists of various systemic therapies including chemotherapy, hormonal therapy, targeted therapy and immunotherapy. Key players in this space provide competitive digital support through branded and unbranded channels. However, patient engagement through unbranded channels to create disease awareness has been more prominent, observes GlobalData, a leading data and analytics […]
Read more

Pharma was forced to shuffle technology investment priorities due to COVID-19

COVID-19 has been a wake-up call for pharma companies to rethink their operations and customer access. Embracing digital transformation will have an important role to play in ensuring that the industry overcomes existing and long-term business challenges, seizes opportunities and continues to thrive in challenging business landscape, says GlobalData, a leading data and analytics company. […]
Read more

While Pfizer and BioNTech’s ‘90% efficacy’ data raises expectations for mRNA vaccines, it will take many more months for key questions to be answered, says GlobalData

Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Experts initially assumed that first iterations of a COVID-19 vaccine would show efficacies not much […]
Read more

Current global contract manufacturing will not keep up with global COVID-19 vaccine demand

A significant proportion of vaccine developers are smaller companies that lack the capacity and funds to manufacture their vaccines in-house. However, there is also simply not enough contract manufacturing capacity worldwide to cope with commercial COVID-19 vaccine demand, says GlobalData, a leading data and analytics company. Adam Bradbury, PharmSource Analyst at GlobalData, comments: “According to GlobalData’s Service Provider Database, there are 195 contract facilities at 123 companies offering vaccine active pharmaceutical ingredient (API) manufacture. It is difficult to […]
Read more

While Pfizer and BioNTech’s ‘90% efficacy’ data raises expectations for mRNA vaccines, it will take many more months for key questions to be answered

Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Experts initially assumed that first iterations of a COVID-19 vaccine would show efficacies not much better than common seasonal influenza vaccines, which are usually only 40–60% effective. At a reported 90%, Pfizer and BioNTech’s […]
Read more

EU Horizon 2020 research and innovation program invested almost €6M ($7.1M) for COVID-19

In response to the COVID-19 pandemic, Horizon 2020 (H2020), the EU’s biggest research and innovation program, invested almost €6M ($7.1M) for COVID-19 related research and drug development in April 2020. This demonstrates how granting agencies have reacted quickly to prioritizing COVID-19 research, says GlobalData, a leading data and analytics company. Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments: “All […]
Read more

Lack of skills and talents poses the biggest challenge to digital transformation in pharmaceutical industry

COVID-19 is set to be a major catalyst for the pharmaceutical industry. The rush to adapt to new social distancing and lockdown norms has led to a hurried digital transformation, leaving many organizations struggling to bridge the digital skills gap, says GlobalData, a leading data and analytics company. GlobalData’s latest report, Digital Transformation and Emerging Technology […]
Read more

FDA likely to approve Biogen’s Aducanumab after its review

Following the release of FDA documents today noting support for the safety and efficacy of Biogen’s treatment for Alzheimer’s Disease (AD), aducanumab, it is looking very likely that the drug will become the first new AD therapy to be approved in 17 years. If it is approved, the drug could be in the market by […]
Read more

COVID-19 is driving more supplier redundancy

Contract development and manufacturing organizations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in the supply chain, says GlobalData, a leading data and analytics company. Peter Shapiro, PharmSource Senior Director of Drugs and Business Fundamentals at GlobalData, comments: “Pharma companies may try to reduce […]
Read more
1 … 75 76 77 78 79 … 108